Editorial: Failing in our Responsibility to Address Obesity Caused by Psychotropic Medications

Obesity is the most common pediatric chronic disease, affecting close to 14.4 million children and adolescents in the US, according to a recent estimate.¹ Despite a significant increase in systematic research and clinical focus in this area, the problem is estimated to worsen in the next 20 years, with estimates predicting that about 57% of children and adolescents between 2 and 19 years of age will be obese by 2050.² Obesity is defined as a body mass index (BMI) at or greater than the 95^th percentile for children and teens of the same age and sex. Because of changes in weight and height with age, and their relation to body fat percentage, BMI levels among children and teens are expressed relative to those of other children of the same sex and age. These percentiles are calculated from the Centers for Disease Control and Prevention (CDC) growth charts, which were based on national survey data collected from 1963-1965 to 1988-1994 (CDC.gov healthy weight webpage). Mental health providers, especially child and adolescent psychiatrists, have an important role in assessing, treating, and even preventing obesity, but current data indicate that we are failing in this responsibility. This is particularly relevant in the context of metabolic side effects of psychotropic agents.